• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»genomic profiling

How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026

By Pallavi Madhiraju on March 19, 2026   Medical Devices & Diagnostics  

How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026

Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.

What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics

By Pallavi Madhiraju on February 20, 2026   Medical Devices & Diagnostics  

What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics

Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.

Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery

By Venkatesh B on December 9, 2025   Medical Devices & Diagnostics  

Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery

Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.

Recent Posts

  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes